Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53
about
The basal transcription machinery as a target for cancer therapyRibosome biogenesis: Achilles heel of cancer?Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?Nucleolar activity in neurodegenerative diseases: a missing piece of the puzzle?Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human diseaseNew insights into nucleolar structure and functionDirect Characterization of Transcription Elongation by RNA Polymerase IOmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumorsDifferential phosphorylation of a regulatory subunit of protein kinase CK2 by target of rapamycin complex 1 signaling and the Cdc-like kinase Kns1.Role of ribosomal protein mutations in tumor development (Review)mTOR inhibitors in cancer therapyYeast Kre33 and human NAT10 are conserved 18S rRNA cytosine acetyltransferases that modify tRNAs assisted by the adaptor Tan1/THUMPD1The human 18S rRNA base methyltransferases DIMT1L and WBSCR22-TRMT112 but not rRNA modification are required for ribosome biogenesisInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingA genome-wide systematic analysis reveals different and predictive proliferation expression signatures of cancerous vs. non-cancerous cellsCcr4-not regulates RNA polymerase I transcription and couples nutrient signaling to the control of ribosomal RNA biogenesisNanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical DevelopmentThe cell proliferation antigen Ki-67 organises heterochromatinGenetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancerSpt6 Is Essential for rRNA Synthesis by RNA Polymerase I.Early nucleolar disorganization in Dictyostelium cell death.Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationp53 is positively regulated by miR-542-3p.The nucleolar size is associated to the methylation status of ribosomal DNA in breast carcinomasNew frontiers in translational control of the cancer genomeThe pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma.A mathematical theory of the transcription repression (TR) therapy of cancer - whether and how it may work.A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.Hira-mediated H3.3 incorporation is required for DNA replication and ribosomal RNA transcription in the mouse zygoteConserved regulators of nucleolar size revealed by global phenotypic analyses.The shared genomic architecture of human nucleolar organizer regions.Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implicationsRibosomal proteins: functions beyond the ribosomeInvolvement of human ribosomal proteins in nucleolar structure and p53-dependent nucleolar stressDysregulation of RNA polymerase I transcription during disease.The Thoc1 ribonucleoprotein and prostate cancer progression.Functional divergence of eukaryotic RNA polymerases: unique properties of RNA polymerase I suit its cellular roleWild type p53 reactivation: from lab bench to clinic.An overview of pre-ribosomal RNA processing in eukaryotesSelective inhibition of rDNA transcription by a small-molecule peptide that targets the interface between RNA polymerase I and Rrn3.
P2860
Q21246017-4C6B87E2-0D24-4F9F-8357-07F55FAFEB3EQ24562064-C5D327FD-2E8F-4AAD-A332-83CD7F29685FQ26785508-C7918C63-AB4C-4425-B0FA-87959AA8C4A4Q26821979-BB0832C8-7AB7-4DDE-82CD-691CF77BE25CQ27005780-50E416E7-E8C0-4D06-A0F5-9F53662046FBQ27015674-896B98D8-24A0-4FCD-AFA9-AAD99EBF71CDQ27334051-7087BECF-DBCF-47CA-8E5C-94BDE5F514ECQ27728475-D1A5476C-839A-4104-B322-D5D0CF2D8622Q27935295-C4BE9FCC-90DC-4800-AAB1-A6B7C48FCAC6Q28068265-926CF1ED-93C6-4797-B816-0BAE77F940CCQ28079129-641F9E5B-46DC-422A-8493-6256811EEA76Q28115864-46C4E5E4-D2A9-4282-B3F9-F10EBF9EFE2AQ28117297-9AE837C6-FC57-47F1-A1ED-39C46EA54E81Q28468631-9A6587EF-FB3A-42F1-BB23-5193F8224746Q28533665-BB706F95-9261-4AAA-89DB-E359116B8E31Q28545102-DF4B3489-B17A-4F44-BF09-A537EF240BA5Q28551246-63581547-349B-4BE0-9B85-C655DA56A6BAQ28592674-98F35F95-DAE8-4314-BEE6-B4176004C326Q30276619-A388253A-9D87-406C-B50B-DDFB1172446FQ30300037-2239B7EC-EC2A-49AF-9749-D63784315B45Q30844769-B85EB5D7-7335-4870-8958-3A0EDB610AA5Q33731216-DBD9D2D0-2101-4D3A-909D-6ED28294FB34Q33758261-997D5B47-ACF9-4C12-9CD5-E2A9257CA256Q33772981-6F1DAAD5-3E19-4901-900E-B60A03D75813Q33853235-44245A8D-B28D-42AE-953E-6B375DF35EEFQ33884719-6678E502-D5AF-412C-902F-C7CD9632807AQ33888911-37B95D86-CB33-4850-A892-09BF964C6EADQ34042569-8B61B104-D7F5-4BEA-9A3E-89935FDF9DD8Q34051667-44183EF5-CE1E-4EFF-948B-CE49692C0CFCQ34365417-3ED7AFF9-83FE-457D-8BE7-36B67B501464Q34367527-1AD14EAB-AC45-470A-872E-FD07A1C54B80Q34435519-FF9D2309-1232-42B3-97AF-171216E40C5CQ34465473-8E09FD63-AA38-4FB7-9D11-9CDE49276BDFQ34529796-2C053380-E3F5-4ECD-9B2D-2FCDA74BDF03Q34645436-53E9FCD4-3BF9-4659-B5DF-F5D114B4B882Q34736122-44B504AC-1F9E-41F7-84DD-283AF210EBB2Q34747109-E946E456-8D37-4272-A090-77FF1F2AC26EQ35146343-0C4B7D9E-7205-48A5-87E2-80335DF8212CQ35180630-FBBF6F6C-5330-478B-BB40-D1077926E4C8Q35208439-520F6323-5401-46F8-B88E-720EF3FF0EA3
P2860
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53
description
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2012
@ast
im Juli 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2012/07/10)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd op 2012/07/10)
@nl
наукова стаття, опублікована в липні 2012
@uk
مقالة علمية (نشرت في 10-7-2012)
@ar
name
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@ast
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@en
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@nl
type
label
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@ast
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@en
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@nl
prefLabel
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@ast
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@en
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Inhibition of RNA polymerase I ...... cer-specific activation of p53
@en
P2093
Abigail Peck
Chris Proffitt
Clemens Schmitt
David M. Ryckman
Denis Drygin
Grant A. McArthur
Joshua Bliesath
Kenna Anderes
Leonie Cluse
Meaghan Wall
P2860
P3181
P356
10.1016/J.CCR.2012.05.019
P577
2012-07-10T00:00:00Z